

## Contents

Preface *XXI*

List of Contributors *XXIII*

### Part One Concepts and Methods for Recombinant Drug Production 1

- 1 Pharmaceutical Biotechnology and Industrial Applications—Learning  
Lessons from Molecular Biology 3**  
*Oliver Kayser and Heribert Warzecha*
- 1.1 Introduction 3
- 1.2 Research Developments 5
- 1.2.1 Protein Engineering 5
- 1.2.2 Muteins 6
- 1.2.3 Post-translational Engineering 7
- 1.2.4 Synthetic Biology 9
- 1.3 Production Hosts and Upstream/Downstream Processing 10
- 1.4 Future Outlook 11
- References 12
- Weblinks 13
- 2 Prokaryotic Cells in Biotech Production 15**  
*Andriy Luzhetskyy, Gabriele Weitnauer, and Andreas Bechthold*
- 2.1 Introduction 15
- 2.2 Production of Natural Products by Microorganisms 15
- 2.2.1 Production of Libraries of Natural Products 16
- 2.2.2 Production of Natural Products by Cloning and Expression of  
Biosynthetic Gene Clusters 18
- 2.2.3 Culture Manipulation to Wake Up Silent Gene Clusters 19
- 2.2.4 Genomic Driven Approaches to Wake Up Silent Gene Clusters 19
- 2.2.5 *E. coli*, an Interesting Host Also for Natural Product Synthesis 19
- 2.2.5.1 Production of Polyketides in *E. coli* 19
- 2.2.5.2 Metabolic Engineering of *E. coli* for Isoprenoid Biosynthesis 20

2.2.6	Global-Scale Strategies for Strains Improvement	21
2.2.6.1	System Biology, System Biotechnology, and “Omic” Approaches	21
2.2.6.2	Synthetic Biology Tools	22
2.2.6.3	Whole Genome Engineering Approaches	24
2.3	Prokaryotes as Producers of Recombinant Therapeutic Proteins	26
2.3.1	Prokaryotic Expression Systems	27
2.3.1.1	Host Strains	27
2.3.1.2	Expression Vectors	31
2.3.2	Production Steps	34
2.3.3	Products	34
2.3.3.1	Somatropin (Somatotropin, STH, Human Growth Hormone, hGH)	34
2.3.3.2	Human Insulin	36
	References	37
<b>3</b>	<b>Mammalian Cells in Biotech Production</b>	<b>43</b>
	<i>Maria J. De Jesus and Florian M. Wurm</i>	
3.1	Introduction	43
3.2	Process Concepts and Cells	44
3.3	CHO-Derived Production Cell Lines	46
3.4	Rapid Generation of High-Producing Cell Lines	47
3.5	Silencing–Stability of Expression	49
3.6	High-Throughput Bioprocess Development	50
3.7	Disposable Bioreactors	51
3.8	Transient Gene Expression (TGE)	52
3.9	Conclusions	53
	References	54
<b>4</b>	<b>Biopharmaceuticals from Plants</b>	<b>59</b>
	<i>Heribert Warzecha</i>	
4.1	Introduction	59
4.2	Basics in Plant Biotechnology	60
4.3	Plant Cell Cultures as Production System for Human Glucocerebrosidase	63
4.4	Insulin from Safflower–A Unique Purification Scheme	64
4.5	Fast and Scalable Transient Tobacco-Based Expression Systems	65
4.6	Conclusion	67
	References	68
<b>5</b>	<b>Production of Biopharmaceuticals in Transgenic Animals</b>	<b>71</b>
	<i>Heiner Niemann, Alexander Kind, and Angelika Schnieke</i>	
5.1	Introduction	71
5.2	Sites of Production	73
5.2.1	Milk	73

5.2.2	Urine	76
5.2.3	Seminal Fluid	77
5.2.4	Blood	77
5.2.5	Bird Eggs	78
5.3	Transgenic Constructs	78
5.3.1	Organ Specific Expression Vectors	80
5.3.2	Inducible Expression	81
5.3.3	Non-integrating Vectors	81
5.4	Methods for the Production of Transgenic Animals	82
5.4.1	Pronuclear DNA Microinjection	83
5.4.1.1	Collection of Fertilized Eggs	83
5.4.1.2	Preparation of DNA	83
5.4.1.3	Injection of DNA	83
5.4.1.4	Transfer and Gestation in Recipients	84
5.4.1.5	Identification of Founders and Subsequent Breeding	85
5.4.2	Viral Mediated Gene Transfer	86
5.4.3	Sperm-Mediated Gene Transfer	88
5.4.4	Transposon-Mediated Gene Transfer	89
5.4.5	Pluripotent Stem Cells	90
5.4.5.1	Embryonic Stem Cells	90
5.4.5.2	Embryonic Germ Cells	91
5.4.5.3	Induced Pluripotent Stem Cells (iPS Cells)	92
5.4.6	Spermatogonial Stem Cells	93
5.4.7	Somatic Cell Nuclear Transfer	94
5.4.8	Highly Specific DNA Endonucleases	99
5.5	Analysis of Transgenic Animals	99
5.5.1	Analysis of Integrated Transgenes	100
5.5.2	Transgene-Expression Profile	101
5.5.3	Collection, Processing, and Protein Purification	101
5.6	Quality and Safety of the Product	102
5.7	Conclusions and Outlook	104
	References	105
<b>6</b>	<b>Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application—and Back Again</b>	<b>113</b>
	<i>Michael Balls, Andrew Bennett, and David Kendall</i>	
6.1	Drug Discovery and Development	113
6.2	The Nature of Models and the Need for Them	114
6.3	New Technologies Toolbox	116
6.3.1	Use of Existing Knowledge	117
6.3.2	<i>In Chemico</i> and Other Physicochemical Approaches	118
6.3.3	<i>In Silico</i> Methods	119
6.3.3.1	<i>In Silico</i> Methods and Drug Discovery	120
6.3.3.2	<i>In Silico</i> Methods and Toxicology	121

6.3.4	<i>In Vitro</i> Systems	122
6.3.4.1	Cell Fractions	122
6.3.4.2	Cell Monolayer or Suspension Cultures	123
6.3.4.3	Co-cultures, Organotypic Cultures, and Reconstituted Tissue Constructs	124
6.3.4.4	Tissue Engineering	125
6.3.4.5	Stem Cells	125
6.3.4.6	Examples of Some Specific <i>In Vitro</i> Systems	127
6.3.4.7	Dynamic Bioreactors	127
6.3.4.8	Multi-organ Systems	128
6.3.4.9	Challenge of Cells, Organs, and Organisms on a Chip	129
6.3.4.10	<i>In Vitro</i> Assays	129
6.3.4.11	Coordinated Approach with <i>In Vitro</i> Models: the Vitrocellomics Project	130
6.3.5	High-Throughput Screening	131
6.3.6	High-Content Screening	131
6.3.7	Omics Approaches	131
6.3.7.1	Variety of Omics	132
6.3.7.2	Application of the Omics	132
6.3.7.3	Handling Information Produced by the Omics	133
6.3.8	Systems Modeling and Simulation	134
6.3.8.1	Pharmacokinetic Modeling	134
6.3.8.2	Virtual Tissue Modeling	135
6.3.8.3	Virtual Patient Populations	136
6.3.9	Biomarkers	136
6.3.10	Clinical Imaging	138
6.3.11	Bioinformatics	140
6.4	Strategic Use of the New Technology Tools	141
6.4.1	The Tools	142
6.4.2	The Strategies	142
6.4.3	Systems Biology	143
6.4.4	Involving the Patient	144
6.5	Translation as a Two-Way Process	145
6.6	Concluding Comment	146
	References	147

## Part Two Bringing the Drug into Action—From Downstreaming to Approval 153

7	<b>Overview and Classification of Approved Recombinant Drugs</b>	155
	<i>Theo Dingermann and Ilse Zündorf</i>	
7.1	Introduction	155
7.2	Classification of Recombinant Drugs from a Technical Point of View	166

- 7.3 Expression Systems 167
- 7.4 Proteins Derived from Modified Genes 170
- 7.5 Artificial Proteins 171
- 7.6 Post-expression Modifications of Recombinant Proteins 173
- 7.7 Biosimilars 174
- References 177

## **8 Downstream Processing 179**

*Uwe Gottschalk*

- 8.1 Introduction 179
- 8.2 General Principles of DSP 180
- 8.3 Clarification 181
  - 8.3.1 Centrifugation 181
  - 8.3.2 Filtration 182
    - 8.3.3 Increasing the Efficiency of Clarification 185
- 8.4 Chromatography 187
  - 8.4.1 Column Chromatography 187
  - 8.4.2 Membrane Chromatography 188
  - 8.4.3 Capture Chromatography 189
  - 8.4.4 Polishing Chromatography 191
  - 8.4.5 Continuous Chromatography 193
- 8.5 Ultrafiltration/Diafiltration, and Virus Filtration 194
  - 8.5.1 Ultrafiltration/Diafiltration 194
  - 8.5.2 Virus Filtration 195
- 8.6 Crystallization 196
- 8.7 Recent Developments in Downstream Processing 196
- References 197

## **9 Characterization of Recombinant Proteins 201**

*Christoph Giese, Henning von Horsten, and Stefan Zietze*

- 9.1 Introduction 201
- 9.2 Physical Chemical Characterization 201
  - 9.2.1 Spectroscopic Methods 201
    - 9.2.1.1 Ultraviolet Absorption Spectroscopy 201
    - 9.2.1.2 Fluorescence Spectroscopy 202
    - 9.2.1.3 Fourier Transform Infrared Spectroscopy 203
  - 9.2.2 Chromatographic Methods 205
    - 9.2.2.1 Size-Exclusion Chromatography 205
    - 9.2.2.2 Reversed-Phase Chromatography 206
    - 9.2.2.3 Hydrophilic Interaction Chromatography 207
    - 9.2.2.4 Ion-Exchange Chromatography 207
  - 9.2.3 Electrophoretic Methods 208
    - 9.2.3.1 Gel Electrophoresis 208
    - 9.2.3.2 Capillary Electrophoresis 209
  - 9.2.4 Other Physical Chemical Methods 210

9.2.5	Mass Spectrometric Analysis of Biopharmaceutical Proteins	211
9.2.5.1	Operating Principle of Mass Spectrometers	211
9.2.5.2	Common Methods for MS Analysis of Biopharmaceuticals	215
9.3	Biological Characterization of Biopharmaceuticals <i>In Vitro</i>	219
9.3.1	Bioassays	219
9.3.1.1	Introduction	219
9.3.1.2	Defining Bioactivity	221
9.3.1.3	Binding Assays	222
9.3.1.4	Bead Array Technology	224
9.3.1.5	Immunogenicity Testing	224
9.3.1.6	Cell-Based Assays (CBA)	225
9.3.1.7	Assay Qualification and Validation	230
9.3.1.8	Outlook	231
	Acknowledgments	232
	Legals	232
	References	232
<b>10</b>	<b>Formulation Strategies for Recombinant Protein and Related Biotech Drugs</b>	<b>235</b>
	<i>Gerhard Winter and Julia Myschik</i>	
10.1	Introduction	235
10.2	Formulation and Stability of Protein Solutions	235
10.2.1	Dry Formulations	238
10.2.2	Modern Formulation Screening Strategies	239
10.2.3	Analytics	240
10.2.4	Formulation Development for the Market	241
10.2.5	Interface between Downstreaming and “Fill and Finish”	242
10.2.6	Highly Concentrated Protein Formulations	243
10.2.7	New Proteins and Related Formulation Aspects	244
10.2.8	Summary	244
10.3	Formulation of Vaccines	245
10.3.1	Analytics	247
	References	248
<b>11</b>	<b>Drug Approval in the European Union and United States</b>	<b>257</b>
	<i>Gary Walsh</i>	
11.1	Introduction	257
11.2	Regulation within the European Union	257
11.2.1	EU Regulatory Framework	257
11.2.2	EMA	259
11.2.3	New Drug Approval Routes	260
11.2.3.1	Centralized Procedure	260
11.3	Regulation in the United States of America	262
11.3.1	CDER and CBER	263
11.3.2	Approvals Procedure	263

11.4	International Regulatory Harmonization	265
11.5	Regulation of Biosimilars	266
<b>12</b>	<b>Patents in the Pharmaceutical Biotechnology Industry: Legal and Ethical Issues</b>	<b>269</b>
	<i>David B. Resnik</i>	
12.1	Introduction	269
12.2	Patent Law	269
12.2.1	What Is a Patent?	269
12.2.2	How Does One Obtain a Patent?	271
12.2.3	What Is the Proper Subject Matter for a Patent?	272
12.2.4	Types of Patents in Pharmaceutical Biotechnology	273
12.2.5	Patent Infringement	273
12.2.6	International Patent Law	274
12.3	Ethical and Policy Issues in Biotechnology Patents	274
12.3.1	No Patents on Nature	275
12.3.2	Threats to Human Dignity	276
12.3.3	Access to Technology	277
12.3.4	Benefit Sharing	280
12.4	Conclusion	281
	References	282
<b>13</b>	<b>Biosimilar Drugs</b>	<b>285</b>
	<i>Walter Hinderer</i>	
13.1	Introduction	285
13.2	Recombinant Therapeutic Proteins	286
13.3	Definition of Biosimilars	287
13.4	Regulatory Situation	290
13.4.1	Basic Principles	290
13.4.2	European Guidelines	291
13.4.3	Regulatory Situation in the United States	294
13.4.4	Regulation in Other Territories	296
13.4.5	Final Remarks	297
13.5	Patent Situation	297
13.6	First Wave of Biosimilars in the EU	305
13.6.1	General Remarks	305
13.6.2	Human Growth Hormone (hGH)	306
13.6.3	Erythropoietin (EPO)	307
13.6.4	Granulocyte-Colony Stimulating Factor (G-CSF)	310
13.6.5	Rejected or Withdrawn Applications: Interferons and Insulin	312
13.6.6	Conclusions on the First-Wave Biosimilars	313
13.7 <sup>xxx</sup>	Biosimilar Targets: Second Wave of Future Biosimilars	313
13.7.1	PEGylated Protein Drugs	313
13.7.2	Recombinant Antibodies and Fc-Fusion Proteins	316
13.8	Biosimilar Developments and Requirements	325

- 13.8.1 Process Development 327
- 13.8.2 Development of Analytical Methods 328
- 13.8.3 Non-clinical and Clinical Development 330
- 13.9 Conclusions 332
- References 333

**14 Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins 337**

*Yi Zhang and Bernd Meibohm*

- 14.1 Introduction 337
- 14.2 Pharmacokinetics of Peptides and Proteins 339
  - 14.2.1 Protein Absorption 339
    - 14.2.1.1 Parenteral Administration 340
    - 14.2.1.2 Inhalation Administration 341
    - 14.2.1.3 Intranasal Administration 342
    - 14.2.1.4 Transdermal Administration 342
    - 14.2.1.5 Oral Administration 343
  - 14.2.2 Protein Distribution 343
  - 14.2.3 Protein Binding 345
  - 14.2.4 Protein Elimination 346
    - 14.2.4.1 Proteolysis 346
    - 14.2.4.2 Gastrointestinal Protein Metabolism 347
    - 14.2.4.3 Renal Protein Metabolism 347
    - 14.2.4.4 Hepatic Protein Metabolism 349
    - 14.2.4.5 Receptor-Mediated Protein Metabolism 349
  - 14.2.5 Role of the Neonatal Fc-Receptor in the Disposition of Proteins 350
- 14.3 Immunogenicity and Protein Pharmacokinetics 352
- 14.4 Exposure–Response Correlations for Protein Therapeutics 353
  - 14.4.1 Direct Link PK/PD Models 354
  - 14.4.2 Indirect Link PK/PD Models 355
  - 14.4.3 Indirect Response PK/PD Models 355
  - 14.4.4 Cell Life Span Models 356
- 14.5 Summary and Conclusions 361
- References 361

**Part Three Vaccines 369**

**15 Scientific, Technical, and Economic Aspects of Vaccine Research and Development 371**

*Jens-Peter Gregersen*

- 15.1 Introduction 371
- 15.2 From the Research Concept to a Development Candidate 372
- 15.3 Vaccine Research Projects 373
- 15.4 Scientific Challenges of Vaccine R&D 375



15.5	Technical Aspects of Vaccine Development	379
15.5.1	Preclinical Development	380
15.5.2	Manufacturing Facilities	381
15.5.3	Clinical Development	382
15.5.4	Licensing and Registration of Vaccine Products	383
15.6	Economic Aspects of Vaccine Development	384
15.6.1	Vaccine Development Cost	384
15.6.2	Risks and Opportunities	386
15.7	Conclusions	387
	References	388
<b>16</b>	<b>New Nanobiotechnological Strategies for the Development of Vectors for Cancer Vaccines</b>	<b>391</b>
	<i>Sean M. Geary, Caitlin D. Lemke, Yogita Krishnamachari, and Aliasger K. Salem</i>	
16.1	Introduction	391
16.2	Biodegradable Nanoparticles	396
16.2.1	Poly( <i>D,L</i> -lactic-co-glycolic Acid) (PLGA) and Polylactic Acid (PLA)	396
16.2.2	Acid-Degradable Hydrogel-Based Particles	398
16.3	Liposomal Nanovectors	399
16.3.1	Conventional Liposomes	400
16.3.2	Long-Circulating Liposomes	400
16.3.3	Positively Charged Liposomes	401
16.3.4	Archaeosomes	402
16.3.5	Fusogenic Liposomes	403
16.4	Gelatin Nanoparticles	404
16.5	Sub-micron Emulsions	404
16.6	Amphiphilic Block-Graft Copolymers	405
16.7	Iron Oxide Nanoparticles	407
16.8	Viruses–Virus-Like Particles–Virosomes	408
16.8.1	Viruses	408
16.8.2	Virus-Like Particles (VLPs)	410
16.8.3	Virosomes	410
16.9	Conclusion	412
	Acknowledgments	412
	References	412
<b>17</b>	<b>Recombinant Vaccines: Development, Production, and Application</b>	<b>423</b>
	<i>Luke R. Le Grand, Michaela White, Evan B. Siegel, and Ross T. Barnard</i>	
17.1	Introduction	423
17.2	Range of Recombinant Vaccines on the Market and in Development Today	424
17.3	Vaccine Dialectic	426
17.4	Comparing Vaccine Efficacy	427

17.5	Vaccines: A Brief Overview	428
17.5.1	Conventional Vaccines	428
17.5.1.1	Whole Organism	428
17.5.1.2	Toxoid	428
17.5.2	Recombinant Vaccines	428
17.5.2.1	Subunit Vaccines	428
17.5.2.2	Conjugate Vaccines	429
17.5.2.3	DNA Vaccines	429
17.5.2.4	T-Cell Receptor Peptide Vaccines and T-Cell Epitope Conjugate Vaccines	430
17.5.2.5	Virus-Like Particles	430
17.5.2.6	Viral Vectors	431
17.5.2.7	Recombinant Attenuated Bacterial Vaccines	433
17.6	Recombinant Vaccine Development	433
17.6.1	Manufacturability	433
17.6.2	Scalability	434
17.6.3	Deliverability and Accessibility	434
17.7	Delivery Systems	435
17.8	At the Vanguard	436
17.8.1	Antigen Targeting	437
17.8.1.1	Resident DCs Crucial to Humoral Immune Responses	437
17.8.2	Prime–Boost Staging	438
17.8.2.1	A Case Study—RTS,S	438
17.8.2.2	Targeting the Conserved/Invariant Region and Multimerizing the Construct	439
17.8.3	Multivalent Antigen Presentation	439
17.8.3.1	Self-Assembling Peptide Nanoparticles for Multivalent Antigen Presentation	440
17.8.3.2	Self-Adjuvanting Agents	441
17.8.4	Adjuvants in Recombinant Vaccines	441
17.9	Novel, Recombinant DNA Approach to Identifying Attenuated Vaccine Strains	442
17.9.1	Combining the Biological with the Molecular	442
17.10	Clinical Trials	443
17.11	Conclusion	443
	References	444

**Part Four Recent Applications in Pharmaceutical Biotechnology 451**

18	<b><i>In Silico</i> and Ultrahigh-Throughput Screenings (uHTS) in Drug Discovery: an Overview</b>	453
	<i>Debmalya Barh, Shoaib Ahmad, and Atanu Bhattacharjee</i>	
18.1	Introduction	453
18.1.1	High-Throughput Screening	453

- 18.1.2 Ensuring Quality, Quantity, and Cost Effectiveness Using Integrated Approaches 454
- 18.1.3 Traditional versus Novel Targets in Lead Discovery 455
- 18.2 *In Silico* Pharmacology and Virtual Ligand Screening for Drug Discovery 456
  - 18.2.1 Quantitative Structure–Activity Relationship (QSAR) 458
  - 18.2.2 Virtual Ligand Screening 459
  - 18.2.3 Virtual Affinity Profiling 459
  - 18.2.4 Data Visualization 460
  - 18.2.5 Applications of *In Silico* Pharmacology 461
- 18.3 Lead Discovery Using Integrative Virtual Screening 461
  - 18.3.1 Target-Based Virtual Screening 462
  - 18.3.2 Ligand-Based Virtual Screening 462
  - 18.3.3 Application of Integrative Virtual Screening 463
    - 18.3.3.1 Case of Cisplatin in Tumor Therapy 463
- 18.4 Application of Microarray Technology in HTS and Drug Discovery 463
  - 18.4.1 DNA Microarray 463
    - 18.4.1.1 DNA Microarray Fabrication 464
    - 18.4.1.2 Application of DNA Microarrays in HTS and Drug Discovery 465
  - 18.4.2 Chemical Microarray for Drug Screening and Discovery 467
    - 18.4.2.1 Chemical Microarray with Immobilized Technology 467
    - 18.4.2.2 Small Molecule Microarray (SMM) 467
    - 18.4.2.3 Dry Chemical Microarray 468
    - 18.4.2.4 Solution Phase Chemical Microarray 468
  - 18.4.3 Cell Microarrays in Screening and Drug Discovery 469
    - 18.4.3.1 Types of Cell Microarrays 469
    - 18.4.3.2 Cell Microarray Formats 470
    - 18.4.3.3 Applications of Cell Microarrays 470
- 18.5 Chemical Proteomics for Drug Discovery and Development 471
  - 18.5.1 Structure of a Probe 471
  - 18.5.2 Strategies in Chemical Proteomics in Drug Discovery 473
    - 18.5.2.1 Activity-Based Probe Profiling 473
    - 18.5.2.2 Fragment-Based Approach 474
    - 18.5.2.3 Applications of Chemical Proteomics 475
- 18.6 Target and Drug Discovery Using Lipomic Profiling 475
  - 18.6.1 Applications of Lipomic Profiling 476
    - 18.6.1.1 Case of Rosiglitazone in Diabetes Mellitus Treatment 476
- 18.7 Drug Discovery Using Integrative Genomics 476
  - 18.7.1 Applications of Integrative Genomics 476
    - 18.7.1.1 Infectomics and Antimicrobial Drug Resistance 477
    - 18.7.1.2 Yeast as Tool for Antifungal Drug Discovery 477
    - 18.7.1.3 Genomics and Proteomics in Antidiabetic Drug Discovery 477
    - 18.7.1.4 Human Genome Project and Anticancer Drug Discovery 477

18.7.1.5	Toxicogenomics for Hepatotoxicity	478
18.8	Toxicogenomics in Drug Discovery and Development	478
18.8.1	Toxicogenomics	478
18.8.2	Toxicogenomics in Drug Discovery	479
18.8.3	Toxicogenomic Studies Using <i>In Vitro</i> Models	480
18.8.4	Toxicogenomic Studies Using Animal Models	480
18.8.5	Toxicogenomics and Gene Polymorphisms	480
18.8.6	Application of Toxicogenomics	481
18.9	HTP RNAi Screening for Targeted Drug Discovery	482
18.9.1	HTS Using RNAi Libraries	482
18.9.2	Applications of RNAi in HTS	483
18.10	High-Throughput Screening with Stem Cells	483
18.10.1	Stem Cell	483
18.10.2	Advantages of Stem Cells	484
18.10.3	Applications of Stem Cells in Screening and Drug Discovery	484
18.11	Systems Biology in Drug Discovery	485
18.11.1	Industry Approaches to Systems Biology	485
18.11.2	Simulation Models	486
18.11.3	Applications of Systems Biology	486
18.12	Conclusion	488
	References	489

## **19 Metabolic Engineering of Medicinal Plants and Microorganisms for the Production of Natural Products 491**

*Oktavia Hendrawati, Herman J. Woerdenbag, Jacques Hille, and Oliver Kayser*

19.1	Introduction	491
19.2	The Plant as a Source of Natural Products	495
19.2.1	Plant Cell Cultures	495
19.2.2	Transgenic Plants	496
19.3	Optimizing Biochemical Pathways	498
19.3.1	Strategies and Goals of Metabolic Engineering	498
19.3.2	Metabolic Pathways of Interest	499
19.3.3	Synthetic Biology	501
19.4	Metabolic Engineering Strategies and Techniques in Medicinal Plant Biotechnology	502
19.4.1	Upregulating of Pathways (Overexpression)	504
19.4.2	Redirecting Common Precursors	505
19.4.3	Targeting Metabolites to Specific Plant Cell Compartments	505
19.4.4	Creation of Storage of Overproduced Secondary Metabolites	506
19.4.5	Downregulating of Pathways (Silencing)	506
19.5	Challenges in Plant Metabolic Engineering	506
19.5.1	Unexplored Regulation of Secondary Metabolism	506
19.5.2	Pathways Are Often Species Specific	507

- 19.5.3 Cell Compartmentalization and Tissue Differentiation 507
- 19.5.4 Unpredicted or Unexpected Outcome 508
- 19.6 Metabolic Engineering Applications in Medicinal Plant Biotechnology 508
- 19.6.1 Case Study: Podophyllotoxin Production in *Anthriscus sylvestris* 508
- 19.6.2 Case Study: Scopolamine Biosynthesis in *Nicotiana tabacum* 509
- 19.6.3 Case Study: Genistein Production in Transgenic *Arabidopsis*, Tobacco, Lettuce, Corn, Petunia, and Tomato 510
- 19.6.4 Case Study: Expression of Spearmint Limone Synthase in Lavender 511
- 19.6.5 Case Study: Artemisinin Biosynthesis in *Artemisia annua* 511
- 19.6.6 Case Study: Morphine Biosynthesis in *Papaver somniferum* 512
- 19.6.7 Case Study: Gossypol Reduction in Cottonseeds by Blocking  $\delta$ -Cadinene Synthase 513
- 19.7 Crossing Borders–Heterologous Production of Plant Compounds in Microorganisms 514
- 19.7.1 Artemisinic Acid 514
- 19.7.2 Stilbenes 514
- 19.7.3 Curcuminoids 515
- 19.7.4 Flavonoids 515
- 19.7.5 Vanillin 516
- 19.8 Conclusion and Future Prospects 516
- References 518

## **20 Metabolomics as a Bioanalytical Tool for Characterization of Medicinal Plants and Their Phytomedical Preparations 527**

*Nizar Happyana, Remco Muntendam, and Oliver Kayser*

- 20.1 Introduction 527
- 20.2 Bioanalytical Tools 528
- 20.2.1 Sample Preparation 530
- 20.2.2 Nuclear Magnetic Resonance 531
- 20.2.3 Mass Spectrometry 532
- 20.2.3.1 Direct Injection Mass Spectrometry 533
- 20.2.3.2 Gas Chromatography–Mass Spectrometry 534
- 20.2.3.3 Liquid Chromatography–Mass Spectrometry 534
- 20.2.4 Data Processing 535
- 20.3 Metabolomics Applications in Medicinal Plants 538
- 20.3.1 Discrimination for Classification of Medicinal Plants 538
- 20.3.2 Characterization of Metabolites in Plant Cultures and Transgenic Medicinal Plants 540
- 20.3.3 Quality Control of Medicinal Plants 541
- 20.3.4 Identification of Medicinal Plant Bioactivity 543
- 20.3.5 Study Efficacy of Medicinal Plants 544
- 20.3.6 Investigation of Medicinal Plant Toxicity 545
- 20.4 Conclusions 546

Acknowledgment 547  
References 547

<b>21</b>	<b>Integration of Biotechnologies for the Development of Personalized Medicine</b>	<b>553</b>
	<i>Kewal K. Jain</i>	
21.1	Introduction	553
21.2	Genetic Variations in the Human Genome	554
21.2.1	Single Nucleotide Polymorphisms	555
21.2.2	Complex Chromosomal Rearrangements	556
21.2.3	Insertions and Deletions in the Human Genome	556
21.2.4	Large-Scale Variation in the Human Genome	557
21.2.5	Variation in Copy Number in the Human Genome	557
21.2.6	Structural Variations in the Human Genome	558
21.3	Role of Biomarkers in the Development of Personalized Medicine	559
21.4	Technologies Used for the Development of Personalized Medicine	560
21.5	Molecular Diagnosis as a Basis for Personalized Medicine	560
21.5.1	Real-Time PCR and Personalized Medicine	561
21.5.2	Analysis of Single Biological Molecules for Personalized Medicine	563
21.5.3	Molecular Imaging and Personalized Medicine	563
21.5.4	Point-of-Care Diagnostics and Personalized Medicine	564
21.6	Sequencing and Personalized Medicine	564
21.6.1	Sequencing of Variations in Human Genomes	565
21.6.2	Study of Rare Variants in Pinpointing Disease-Causing Genes	565
21.7	Role of Biochips/Microarrays in the Development of Personalized Medicine	566
21.8	Role of Cytogenetics in the Development of Personalized Medicine	567
21.9	Role of “Omics” in Personalized Medicine	568
21.9.1	Role of Pharmacogenetics	568
21.9.2	Role of Pharmacogenomics	569
21.9.3	Role of Pharmacoproteomics	570
21.9.4	Role of Pharmacometabolomics	570
21.10	Role of Nanobiotechnology for the Development of Personalized Medicine	572
21.11	Systems Biology and Personalized Medicine	573
21.12	Personalized Biological Therapies	574
21.12.1	Recombinant Human Proteins	575
21.12.2	Therapeutic Monoclonal Antibodies	575
21.12.3	Cell Therapy	575
21.12.4	Gene Therapy	576
21.12.5	RNA Interference	576

- 21.13 Personalized Vaccines 577
- 21.13.1 Personalized Vaccines for Viral Diseases 577
- 21.13.2 Personalized Cancer Vaccines 577
- 21.14 Concluding Remarks and Future Prospects of Personalized  
Medicine 578
- References 579
  
- 22 Xenotransplantation in Pharmaceutical Biotechnology 581**  
*Gregory J. Brunn and Jeffrey L. Platt*
- 22.1 Introduction 581
- 22.1.1 Alternative Sources of Transplantable Tissues 581
- 22.1.2 The Pig as a Source of Tissues and Organs for Clinical  
Xenotransplantation 582
- 22.2 Biological Barriers to Xenotransplantation 583
- 22.2.1 Graft Vascularization 583
- 22.2.2 Hyperacute Rejection 584
- 22.2.3 Complement Activation 585
- 22.2.4 Acute Vascular Rejection 586
- 22.2.5 Accommodation 588
- 22.2.6 Cellular Mediated Immune Responses 588
- 22.3 Physiological and Infectious Hurdles to Xenotransplantation 590
- 22.3.1 Interspecies Challenges 590
- 22.3.2 Zoonosis 591
- 22.4 Scenario for the Clinical Application of Xenotransplantation 592
- References 593
  
- 23 Nutraceuticals–Functional Foods for Improving Health and Preventing  
Disease 599**  
*Jian Zhao*
- 23.1 Introduction 599
- 23.2 Plant Food, Pharmaceuticals, Nutraceuticals, and Human  
Health 600
- 23.3 Concepts of Functional Foods, Nutraceuticals, and Other Related  
Terms 601
- 23.3.1 Functional Foods 602
- 23.3.2 Nutraceutical 602
- 23.3.3 Medical Foods 603
- 23.3.4 Novel Foods 603
- 23.3.5 Food (Dietary) Supplement 604
- 23.3.6 Food Additives 604
- 23.3.7 Phytonutrients 604
- 23.3.8 Herbs, Herbal Nutraceuticals, or Botanicals 605
- 23.3.9 Alternative Therapies 605
- 23.4 FFN Principles and Their Potential Health Benefits 606
- 23.4.1 Dietary Fibers 606

XX | Contents

23.4.2	Phenolic Products	607
23.4.3	Terpenoids	608
23.4.4	Phytosterols	609
23.4.5	Fatty Acids and Lipids	609
23.4.6	Essential Amino Acids	610
23.4.7	Prebiotics and Probiotics	611
23.4.8	Phytoestrogen	612
23.5	Herbal Nutraceuticals and Multiple Herbal Component Formulations	613
23.6	FFNs and Metabolic Syndrome, Facial Aging, and Cosmetic Surgery	614
23.7	Absorption and Metabolism of FFNs and Interaction with Drugs	616
23.8	Epidermiological Study and Clinical Trials on FFNs	618
23.9	Biotechnology for Improved Nutritional Value and Creation of Medical Foods	619
23.10	Future Developments	621
	References	622

**Index** 629